Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride

IF 2.8 3区医学 Q2 PSYCHIATRY

Asia‐Pacific Psychiatry Pub Date : 2021-03-22 DOI:10.1111/appy.12469

Wang Zhenhua, Chen Haizhi, Li Jing, Fei Xiaocong, Li Jianhua, Liu Jianjun, Lei Lilei, Jin Haiying

{"title":"Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride","authors":"Wang Zhenhua, Chen Haizhi, Li Jing, Fei Xiaocong, Li Jianhua, Liu Jianjun, Lei Lilei, Jin Haiying","doi":"10.1111/appy.12469","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To investigate macroprolactinemia caused by antipsychotics and its clinical significance.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 133 patients with schizophrenia were selected, all of whom were treated with either risperidone or amisulpride alone. The levels of total prolactin (T-PRL) and macroprolactin (MPRL) were measured before treatment as well as the second, fourth, and sixth weeks of treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>After 2 weeks of treatment, 75.09% (100/133) of the patients met the diagnostic criteria for hyperprolactinemia, the incidence of macroprolactinemia was 43% (43/100), and MPRL levels were positively correlated T-PRL levels.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia.</p>\n </section>\n </div>","PeriodicalId":8618,"journal":{"name":"Asia‐Pacific Psychiatry","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2021-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/appy.12469","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia‐Pacific Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/appy.12469","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 1

Abstract

Objective

To investigate macroprolactinemia caused by antipsychotics and its clinical significance.

Methods

A total of 133 patients with schizophrenia were selected, all of whom were treated with either risperidone or amisulpride alone. The levels of total prolactin (T-PRL) and macroprolactin (MPRL) were measured before treatment as well as the second, fourth, and sixth weeks of treatment.

Results

After 2 weeks of treatment, 75.09% (100/133) of the patients met the diagnostic criteria for hyperprolactinemia, the incidence of macroprolactinemia was 43% (43/100), and MPRL levels were positively correlated T-PRL levels.

Conclusion

Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia.

查看原文本刊更多论文

利培酮或氨硫pride治疗精神分裂症患者巨催乳素血症的发生

目的探讨抗精神病药物引起的巨催乳素血症及其临床意义。方法选择133例精神分裂症患者，均采用利培酮或阿米硫pride单独治疗。治疗前及治疗第2、4、6周测定总催乳素(T-PRL)和巨催乳素(MPRL)水平。结果治疗2周后，75.09%(100/133)的患者符合高催乳素血症的诊断标准，巨催乳素血症的发生率为43% (43/100)，MPRL水平与T-PRL水平呈正相关。结论利培酮和氨硫pride引起高催乳素血症和大催乳素血症;因此，在临床环境中应检测MPRL，因为这种现象在治疗早期(第二周)出现并持续，这可以避免对无症状的巨催乳素血症患者进行不必要的检查和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia‐Pacific Psychiatry PSYCHIATRY-

CiteScore

7.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Asia-Pacific Psychiatry is an international psychiatric journal focused on the Asia and Pacific Rim region, and is the official journal of the Pacific Rim College of Psychiatrics. Asia-Pacific Psychiatry enables psychiatric and other mental health professionals in the region to share their research, education programs and clinical experience with a larger international readership. The journal offers a venue for high quality research for and from the region in the face of minimal international publication availability for authors concerned with the region. This includes findings highlighting the diversity in psychiatric behaviour, treatment and outcome related to social, ethnic, cultural and economic differences of the region. The journal publishes peer-reviewed articles and reviews, as well as clinically and educationally focused papers on regional best practices. Images, videos, a young psychiatrist''s corner, meeting reports, a journal club and contextual commentaries differentiate this journal from existing main stream psychiatry journals that are focused on other regions, or nationally focused within countries of Asia and the Pacific Rim.